LivaNova PLC (BVMF:L2IV34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 27.26B +83.3% |
| Revenue (ttm) | 7.81B +11.7% |
| Net Income | 1.02B |
| EPS | 2.41 |
| Shares Out | n/a |
| PE Ratio | 22.65 |
| Forward PE | 19.22 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 54.60 |
| Previous Close | 54.60 |
| Day's Range | 54.60 - 54.60 |
| 52-Week Range | 41.64 - 54.60 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About LivaNova
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead th... [Read more]
News
LivaNova Transcript: UBS Global Healthcare Conference
Core cardiopulmonary and epilepsy growth is being supported by improved supply, reimbursement and VNS clinical data. OSA plans target $200M-$400M revenue by 2030, with a PMA filing targeted for H2 2026 to H1 2027.
LivaNova price target raised to $120 from $105 at Barclays
Barclays raised the firm’s price target on LivaNova (LIVN) to $120 from $105 and keeps an Overweight rating on the shares. The firm says the company’s “strong” Q3 report increases…
LivaNova price target raised to $115 from $95 at Mizuho
Mizuho raised the firm’s price target on LivaNova (LIVN) to $115 from $95 and keeps an Outperform rating on the shares.
LivaNova price target raised to $111 from $95 at Baird
Baird raised the firm’s price target on LivaNova (LIVN) to $111 from $95 and keeps an Outperform rating on the shares. The firm updated its model following beat and raise…
LivaNova price target raised to $120 from $100 at Jefferies
Jefferies raised the firm’s price target on LivaNova (LIVN) to $120 from $100 and keeps a Buy rating on the shares following strong Q3 results and raised guidance. The firm…
LivaNova price target raised to $112 from $93 at Needham
Needham raised the firm’s price target on LivaNova (LIVN) to $112 from $93 and keeps a Buy rating on the shares.
LivaNova Earnings Call Transcript: Q3 2026
Q3 revenue increased 10% to $393m, led by Cardiopulmonary and Epilepsy growth. FY2026 revenue and adjusted EPS guidance rose, while free cash flow guidance held; oxygenator capacity expansion and OSA development remain key investments.
LivaNova Earnings release: Q3 2026
LivaNova released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
LivaNova Slides: Q3 2026
LivaNova has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 4, 2026.
LivaNova Quarterly report: Q3 2026
LivaNova has published its Q3 2026 quarterly earnings report on November 4, 2026.
LivaNova raises FY26 adjusted EPS view to 4.40-$4.50 from $4.30-$4.40
Raises FY26 revenue view up 9%-10% from 8%-9%. Consensus is for FY26 EPS $4.36 and for revenue $1.52B. Foreign currency is expected to be a tailwind of approximately 1% based…
LivaNova reports Q3 adjusted EPS $1.23, consensus $1.06
Reports Q3 revenue $393.1M, consensus $381.11M. “Our team continues to deliver robust revenue growth driven by commercial execution and healthy global demand for our Cardiopulmonary and Epilepsy techn...
LivaNova Reports Third-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the third quarter ended September 30, 2026 and...
LivaNova announces Neuromodulation published 36-month results from CORE-VNS
LivaNova (LIVN) announced that the journal Neuromodulation: Technology at the Neural Interface has published the full 36-month results from the CORE-VNS study, the first long-term effectiveness evalua...
Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova's VNS Therapy for Drug-Resistant Epilepsy
GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Neuromodulation: Technology at the Neura...
LivaNova to Present at UBS, Wolfe, Stifel, and Jefferies Healthcare Conferences in November
GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that members of the Company's Executive Leadership Team w...
LivaNova initiated with an Overweight at Barclays
Barclays analyst Christopher Pasquale initiated coverage of LivaNova (LIVN) with an Overweight rating and $105 price target The firm rolled out coverage of the medical suppliers and devices group with...
LivaNova to Announce Third-Quarter 2026 Results
GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2026 results on ...
LivaNova Transcript: 2026 Global Healthcare Conference
Sustained double-digit growth is driven by talent, execution, and innovation, with new reimbursement and clinical data providing strong tailwinds. Margin expansion will be reinvested in OSA, while next-gen products and digital upgrades are set to drive future growth across epilepsy and cardiopulmonary segments.
LivaNova Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Core businesses in cardiopulmonary and epilepsy are driving sustainable growth, supported by innovation, improved reimbursement, and supply chain enhancements. Expansion into OSA with differentiated technology and a robust pipeline is expected to accelerate growth, while capital allocation focuses on reinvestment and selective M&A.
LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September
GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the two following September healthcare...
LivaNova price target raised to $90 from $87 at Piper Sandler
Piper Sandler raised the firm’s price target on LivaNova (LIVN) to $90 from $87 and keeps an Overweight rating on the shares. Following concerns over the U.S. cardiopulmonary Q2 result…
LivaNova selloff brings attractive entry point, says Mizuho
Mizuho believes the post-earnings selloff in shares of LivaNova (LIVN) provides an attractive entry point. After meeting with management, the firm believes the outlook for at least high-single-digit g...
LivaNova price target raised to $85 from $80 at Stifel
Stifel raised the firm’s price target on LivaNova (LIVN) to $85 from $80 and keeps a Buy rating on the shares. The optics of slowing U.S. cardiopulmonary growth are “more…
LivaNova price target raised to $93 from $81 at Needham
Needham raised the firm’s price target on LivaNova (LIVN) to $93 from $81 due to peer multiple expansion, while keeping a Buy rating on the shares. The firm notes the…